Topline data from FIBRONEERtm-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 ...
Sen-Jam Pharmaceutical, a pioneering biotech company dedicated to innovative anti-inflammatory solutions, is pleased to announce its engagement with Destum Partners, a leading advisory firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback